Atomwise, a San Francisco-based drug discovery company, launched its Artificial Intelligence Molecular Screen program.
The AIMS program seeks research proposals from university scientists studying various diseases. In a proposal, the research lab will specify what disease and protein they want to target. After selecting up to 100 labs for the program, Atomwise will use its AtomNet deep learning platform to screen millions of molecules and potential drug treatments.
Ultimately, the selected labs will receive 72 drug compound suggestions, custom-chosen by the artificial intelligence software. Atomwise will provide the winners of the AIMS program this drug discovery service for free.
"Global health crises are mounting and universities are facing cutbacks in research funding," Atomwise Co-Founder and COO Alexander Levy said. "Initiatives like AIMS are stepping in to help ensure we don't lose the next generation of medical breakthroughs."